Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Le, XiuningXiuningLeSakai, HiroshiHiroshiSakaiFelip, EnriquetaEnriquetaFelipVeillon, RemiRemiVeillonGarassino, Marina ChiaraMarina ChiaraGarassinoRaskin, JoJoRaskinCortot, Alexis BAlexis BCortotViteri, SantiagoSantiagoViteriMazieres, JulienJulienMazieresSmit, Egbert FEgbert FSmitThomas, MichaelMichaelThomasIams, Wade TWade TIamsCho, Byoung ChulByoung ChulChoKim, Hye RyunHye RyunKimCHIH-HSIN YANGChen, Yuh-MinYuh-MinChenPatel, Jyoti DJyoti DPatelBestvina, Christine MChristine MBestvinaPark, KeunchilKeunchilParkGriesinger, FrankFrankGriesingerJohnson, MelissaMelissaJohnsonGottfried, MayaMayaGottfriedBritschgi, ChristianChristianBritschgiHeymach, JohnJohnHeymachSikoglu, ElifElifSikogluBerghoff, KarinKarinBerghoffSchumacher, Karl-MariaKarl-MariaSchumacherBruns, RolfRolfBrunsOtto, GordonGordonOttoPaik, Paul KPaul KPaik2023-03-022023-03-022022-03-151078-0432https://scholars.lib.ntu.edu.tw/handle/123456789/628829Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.enCELL LUNG-CANCER; CAPMATINIB; MUTATIONS; AMPLIFICATION; INHIBITORS; DIAGNOSIS; SURVIVAL; IMPACTTepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practicejournal article10.1158/1078-0432.CCR-21-2733347894812-s2.0-85121458417WOS:000772148300001https://api.elsevier.com/content/abstract/scopus_id/85121458417